Exelixis
EXEL
#1695
Rank
NZ$17.22 B
Marketcap
$60.33
Share price
-3.83%
Change (1 day)
60.50%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

EPS for Exelixis (EXEL)

EPS in 2023 (TTM): $0.47

According to Exelixis's latest financial reports the company's current EPS (TTM) is $0.49. In 2022 the company made an earnings per share (EPS) of $0.99 a decrease over its 2021 EPS that were of $1.29.

EPS history for Exelixis from 2000 to 2023

Annual EPS

Year EPS Change
2023 (TTM)$0.47-52.86%
2022$0.99-22.97%
2021$1.29100%
2020$0.64-65.09%
2019$1.84-53.91%
2018$4.00333.96%
2017$0.92-260.61%
2016-$0.57-58.75%
2015-$1.39-42.45%
2014-$2.425.3%
2013-$2.3043.48%
2012-$1.60-264.29%
2011$0.97-165.88%
2010-$1.48-32.54%
2009-$2.19-17.65%
2008-$2.6675.86%
2007-$1.51-25.64%
2006-$2.038.33%
2005-$1.88-42.86%
2004-$3.2930.34%
2003-$2.52-5.23%
2002-$2.66-0.65%
2001-$2.68-51.88%
2000-$5.56

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
$6.09 1,135.69%๐Ÿ‡ฌ๐Ÿ‡ง UK
$5.53 1,022.57%๐Ÿ‡ซ๐Ÿ‡ท France
$3.17 543.02%๐Ÿ‡บ๐Ÿ‡ธ USA
$6.90 1,301.34%๐Ÿ‡บ๐Ÿ‡ธ USA
$24.61 4,894.71%๐Ÿ‡บ๐Ÿ‡ธ USA
$24.49 4,871.87%๐Ÿ‡บ๐Ÿ‡ธ USA
$3.23 556.55%๐Ÿ‡บ๐Ÿ‡ธ USA
-$17.39-3,629.83%๐Ÿ‡บ๐Ÿ‡ธ USA
-$1.46-396.51%๐Ÿ‡บ๐Ÿ‡ธ USA